LACE+指数预测幕上肿瘤手术90天结局
本研究回顾性计算624例幕上肿瘤手术患者的LACE+评分,采用粗化精确匹配控制混杂,比较不同评分四分位组患者90天内非计划再入院、急诊就诊和死亡频率。结果显示高LACE+评分与再入院、急诊就诊及死亡风险显著增加相关,提示LACE+或可用于此类人群的围手术期风险分层。
要点
- LACE+评分越高,90天再入院和急诊就诊风险显著增加。
- 高LACE+评分与术后90天内及随访期间死亡风险升高相关。
- LACE+可能适用于幕上肿瘤手术患者的围手术期风险分层。
核心结论
- LACE+可能适合用于描述幕上脑肿瘤切除术患者特定围手术期事件的风险。
研究设计与样本
- 回顾性研究,纳入2017-2019年宾夕法尼亚大学健康系统624例幕上肿瘤手术患者,计算LACE+评分。
- 采用粗化精确匹配控制混杂变量,比较不同LACE+评分四分位组(Q1-Q4)的结局频率。
临床怎么用
- 可利用LACE+评分识别幕上肿瘤术后高再入院、急诊就诊及死亡风险患者,辅助围手术期管理决策。
局限性
- 回顾性单中心研究,样本量624例,结论需外部验证。
- LACE+评分在神经外科人群中的预测效能尚未在前瞻性研究中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The LACE+ (Length of stay, Acuity of admission, Charlson Comorbidity Index [CCI] score, and Emergency department [ED] visits in the past 6 mo) index risk-prediction tool has never been successfully tested in a neurosurgery population. OBJECTIVE: To assess the ability of LACE+ to predict adverse outcomes after supratentorial brain tumor surgery. METHODS: LACE+ scores were retrospectively calculated for all patients (n = 624) who underwent surgery for supratentorial tumors at the University of Pennsylvania Health System (2017-2019). Confounding variables were controlled with coarsened exact matching. The frequency of unplanned hospital readmission, ED visits, and death was compared for patients with different LACE+ score quartiles (Q1, Q2, Q3, and Q4). RESULTS: A total of 134 patients were matched between Q1 and Q4; 152 patients were matched between Q2 and Q4; and 192 patients were matched between Q3 and Q4. Patients with higher LACE+ scores were significantly more likely to be readmitted within 90 d (90D) of discharge for Q1 vs Q4 (21.88% vs 46.88%, P = .005) and Q2 vs Q4 (27.03% vs 55.41%, P = .001). Patients with larger LACE+ scores also had significantly increased risk of 90D ED visits for Q1 vs Q4 (13.33% vs 30.00%, P = .027) and Q2 vs Q4 (22.54% vs 39.44%, P = .039). LACE+ score also correlated with death within 90D of surgery for Q2 vs Q4 (2.63% vs 15.79%, P = .003) and with death at any point after surgery/during follow-up for Q1 vs Q4 (7.46% vs 28.36%, P = .002), Q2 vs Q4 (15.79% vs 31.58%, P = .011), and Q3 vs Q4 (18.75% vs 31.25%, P = .047). CONCLUSION: LACE+ may be suitable for characterizing risk of certain perioperative events in a patient population undergoing supratentorial brain tumor resection.
引用
- Winter E, Haldar D, Glauser G, et al. The LACE+ Index as a Predictor of 90-Day Supratentorial Tumor Surgery Outcomes. Neurosurgery. 2020. PMID: 32542339. doi:10.1093/neuros/nyaa225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。